國家衛生研究院 NHRI:Item 3990099045/6890

NHRI > National Institute of Infectious Diseases and Vaccinology > Chi-Jung Wu > Periodical Articles > Item 3990099045/6890

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6890

Title:	Effects of PPARgamma and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy
Other Titles:	Effects of PPARγ and RBP4 Gene Variants on Metabolic Syndrome in HIV-Infected Patients with Anti-Retroviral Therapy
Authors:	Hung, YP;Lee, NY;Lin, SH;Chang, HC;Wu, CJ;Chang, CM;Chen, PL;Lin, HJ;Wu, YH;Tsai, PJ;Tsai, YS;Ko, WC
Contributors:	Division of Infectious Diseases
Abstract:	Background: PPARγ and RBP4 are known to regulate lipid and glucose metabolism and insulin resistance. The influences of PPARγ (C1431T and Pro12Ala) and RBP4 (−803GA) polymorphisms on metabolic syndrome in HIV-infected patients receiving anti-retroviral therapy were examined in this study. Materials and Methods:A cross-sectional study of HIV-1 infected adults with antiretroviral therapy for more than one year in the National Cheng Kung University Hospital was conducted. The gene polymorphisms were determined by quantitative PCR. Results:Ninety-one patients were included in the study. Eighty-two (90.1%) patients were males with a mean age of 44.4 years. For the C1431T polymorphism in PPARγ, while patients with the T allele (48.4%) had trends toward lower rate of hypertriglyceridemia, the borderline significance together with insignificant power did not support the protective effect of the T allele against development of hypertriglyceridemia. For the Pro12Ala polymorphism in PPARγ, although patients with the Pro/Ala genotype (8.8%) had a higher level of serum LDL (138.0 vs. 111.5 mg/dl, P = 0.04) and trends toward higher rates of hypercholesterolemia and serum LDL>110 mg/dl, these variables were found to be independent of the Pro/Ala genotype in the multivariate analysis. For the −803GA polymorphism in RBP4, patients with the A allele (23.1%) more often had insulin resistance (HOMA>3.8; 33.3 vs. 8.7%, P = 0.01) and more often received anti-hypoglycemic drugs (14.3 vs. 1.4%, P = 0.04). The detrimental effect of the A allele in RBP4 −803GA polymorphism on development of insulin resistance was supported by the multivariate analysis adjusting for covariates. Conclusion:The impacts of PPARγ C1431T and Pro12Ala polymorphisms on metabolism in HIV-infected patients are not significant. RBP4 −803GA polymorphism has increased risk of insulin resistance in HIV-infected patients with anti-retroviral therapy.
Date:	2012-11-07
Relation:	PLoS ONE. 2012 Nov 7;7(11):Article number e49102.
Link to:	http://dx.doi.org/10.1371/journal.pone.0049102
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1932-6203&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000311935800205
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84868673212
Appears in Collections:	[Chi-Jung Wu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PLO2012120105.pdf		238Kb	Adobe PDF	476	View/Open

Loading...